BM-hMSCs presented a statistically significant decrease of aggrecan in the presence of hPL, in both scaffolds (Scaffold HC1 OM+hPL vs. OM+FBS, p = 0.044; Scaffold HC1 GM+hPL vs. OM+FBS, p = 0.047; Scaffold HC2 OM+hPL vs. OM+FBS, p = 0.0315; Scaffold HC2 GM+hPL vs. OM+FBS, p = 0.0324; scaffold HC2 GM+hPL vs. GM+FBS, p = 0.046). Here, ACAN is linked to ocular melanoma.